In TRANSCEND FL, 95.7% of patients with high-risk relapsed or refractory follicular lymphoma (FL)treated with Breyanzi in the second-line setting achieved a complete response, with median duration of response and median progression-free survival not reached at a median follow-up of 16.8 months
Breyanzi showed a manageable safety profile in 2L FL, with no new safety signals and no occurrences of Grade ≥3 cytokine release syndrome and